Literature DB >> 28161246

Partial agonism at the α7 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats.

Andrew Hayward1, Lisa Adamson2, Joanna C Neill3.   

Abstract

Inattention is a disabling symptom in conditions such as schizophrenia and attention deficit/hyperactivity disorder. Nicotine can improve attention and vigilance, but is unsuitable for clinical use due to abuse liability. Genetic knockout of the α7 nicotinic acetylcholine receptor (nAChR) induces attention deficits therefore selective agonism may improve attention, without the abuse liability associated with nicotine. The α7 nAChR partial agonist encenicline (formerly EVP-6124) enhances memory in rodents and humans. Here we investigate, for the first time, efficacy of encenicline to improve attention and vigilance in animals behaviourally grouped for low attentive traits in the 5 choice-continuous performance task (5C-CPT). Female Lister Hooded rats were trained to perform the 5C-CPT with a variable stimulus duration (SD). Animals were then grouped based on performance into upper and lower quartiles of d' (vigilance) and accuracy (selective attention), producing high-attentive (HA) and low-attentive (LA) groups. LA animals showed an increase in selective attention and vigilance at 0.3mg/kg encenicline, a reduction in impulsive action (probability of false alarms) and increase in vigilance following 1mg/kg at 0.75sSD. At 1mg/kg, HA animals had reduced selective attention at 0.75sSD and reduced vigilance at 0.75 and 1.25sSD. Improvement of attention, vigilance and impulsive action in LA animals demonstrates that encenicline has pro-attentive properties dependent on baseline levels of performance. Our work suggests that α7 nAChR partial agonism may improve attention particularly in conditions with low attention.
Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  5 choice-continuous performance task; 5C-CPT; Animal Model; Behavioural separation; Low attentive; α7 nAChR

Mesh:

Substances:

Year:  2017        PMID: 28161246     DOI: 10.1016/j.euroneuro.2017.01.013

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

1.  Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence.

Authors:  Randi Melissa Schuster; Gladys N Pachas; Luke Stoeckel; Corinne Cather; Mireya Nadal; David Mischoulon; David A Schoenfeld; Haiyue Zhang; Christine Ulysse; Elisabeth B Dodds; Sara Sobolewski; Vicenta Hudziak; Ailish Hanly; Maurizio Fava; A Eden Evins
Journal:  J Clin Psychopharmacol       Date:  2018-08       Impact factor: 3.153

2.  Preclinical Evaluation of Attention and Impulsivity Relevant to Determining ADHD Mechanisms and Treatments.

Authors:  Johnny A Kenton; Jared W Young
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs.

Authors:  Adam C Mar; Simon R O Nilsson; Begoña Gamallo-Lana; Ming Lei; Theda Dourado; Johan Alsiö; Lisa M Saksida; Timothy J Bussey; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2017-07-26       Impact factor: 4.530

4.  Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.

Authors:  Michael R Weed; Joseph Polino; Laura Signor; Mark Bookbinder; Deborah Keavy; Yulia Benitex; Daniel G Morgan; Dalton King; John E Macor; Robert Zaczek; Richard Olson; Linda J Bristow
Journal:  PLoS One       Date:  2017-12-19       Impact factor: 3.240

Review 5.  Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits.

Authors:  Manoranjan S D'Souza
Journal:  Front Psychiatry       Date:  2019-07-24       Impact factor: 4.157

6.  Receptor variants and the development of centrally acting medications
.

Authors:  Stuart A Neale; Kumiko Kambara; Thomas E Salt; Daniel Bertrand
Journal:  Dialogues Clin Neurosci       Date:  2019       Impact factor: 5.986

7.  Potential Targets and Action Mechanism of Gastrodin in the Treatment of Attention-Deficit/Hyperactivity Disorder: Bioinformatics and Network Pharmacology Analysis.

Authors:  Zhe Song; Guangzhi Luo; Chengen Han; Guangyuan Jia; Baoqing Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-12       Impact factor: 2.650

8.  Aged rhesus monkeys: Cognitive performance categorizations and preclinical drug testing.

Authors:  Marc R Plagenhoef; Patrick M Callahan; Wayne D Beck; David T Blake; Alvin V Terry
Journal:  Neuropharmacology       Date:  2021-02-06       Impact factor: 5.250

Review 9.  The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.

Authors:  Taoyi Yang; Ting Xiao; Qi Sun; Kewei Wang
Journal:  Acta Pharm Sin B       Date:  2017-10-16       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.